Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer

Clinical Genitourinary Cancer

Volumn 12, Issue 2, 2014, Pages 71-73

  Sonpavde, Guru ^a   Galsky, Matthew D ^b   Latini, David ^c   Chen, Guoqing J ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Mt Sinai Tisch Cancer Institute   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL PRODUCT; CARBOPLATIN; CISPLATIN; GEMCITABINE; NEW DRUG; SUNITINIB;

ADVANCED BLADDER CANCER; ADVANCED CANCER; BLADDER CANCER; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG DEVELOPMENT; HOSPITAL PATIENT; HUMAN; KIDNEY FUNCTION; METASTASIS; NOTE; OUTPATIENT; SOCIOECONOMICS;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG DISCOVERY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84896405606     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.11.016     Document Type: Note

References (18)

1. C.J. Logothetis, F.H. Dexeus, and L. Finn et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055.
2. H. von der Maase, S.W. Hansen, and J.T. Roberts et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077.
3. S.B. Saxman, K.J. Propert, and L.H. Einhorn et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 15 1997 2564 2569.
4. P.J. Loehrer Sr., L.H. Einhorn, and P.J. Elson et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073.
5. C.N. Sternberg, P. de Mulder, and J.H. Schornagel et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 2006 50 54.
6. H. von der Maase, L. Sengelov, and J.T. Roberts et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608.
7. M.D. Galsky, N.M. Hahn, and J. Rosenberg et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy Lncet Oncol 12 2011 211 214.
8. M.D. Galsky, N.M. Hahn, and J. Rosenberg et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy J Clin Oncol 29 2011 2432 2438.
9. A. Dash, M.D. Galsky, and A.J. Vickers et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506 513.
10. M.D. Galsky, G.J. Chen, and W.K. Oh et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma Ann Oncol 23 2012 406 410.
11. M. De Santis, J. Bellmunt, and G. Mead et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 J Clin Oncol 30 2012 191 199.
12. G. Sonpavde, D. Watson, and M. Tourtellott et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community Clin Genitourin Cancer 10 2012 1 5.
13. J. Bellmunt, J.L. Gonzalez-Larriba, and C. Prior et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity Ann Oncol 22 2011 2646 2653.
14. A.V. Balar, A.B. Apolo, and I. Ostrovnaya et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer J Clin Oncol 31 2013 724 730.
15. G. Sonpavde, M.D. Galsky, and N.J. Vogelzang First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? J Clin Oncol 28 2010 e441 e442 author reply e3-4.
16. S.A. Hussain, D.D. Stocken, and P. Riley et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer Br J Cancer 91 2004 844 849.
17. B.L. Maughan, N. Agarwal, and S.A. Hussain et al. Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma Clin Genitourin Cancer 11 2013 316 320.
18. A.C. Small, C.K. Tsao, and E.L. Moshier et al. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy Cancer 118 2012 5947 5954